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in the review illustrate the problems that may be encountered in comparing cost-
effectiveness estimates of different vaccination programs among themselves as
well as with other prevention or treatment interventions.
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OBJECTIVES: Individual data sources contain non-integrated data components
needed to assess outcomes, resource use, and costs in cancer patients. This work
describes methodology to integrate disparate electronic data sources in chronic
myelogenous leukemia (CML) patients with a common identifier (CI).METHODS: A
CML Patient cohort from the Huntsman Cancer Institute was created by extracting
information across theUtahCancer Registry; theUtah PopulationDatabase (UPDB);
and the Enterprise Data Warehouse, including Cerner inpatient and EPIC ambula-
tory care clinic data. Medication use was from inpatient medication orders. A
unique patient index identifier linked disparate records. RESULTS: A total of 602
patients were identified by ICD-9 diagnosis code for CML (250.1, 205.10-12) from
1995 through 2009,median age 51, 42.6% female. Of these 598 (99.3%) were linked
to the UPDB and 245 had a state death certificate. Charlson Comorbidity Index (CCI)
analysis (/ 90 days) identified 232 (38.5%) subjects with a score of zero, 199
(33.1%) with 1-3, 99 (16.4%) with 4-6, 47 (7.8%) with 7-9 and 25 (4.2%) with a score of
10-17 (median2,mean 2.6, and SD 3.1). Inpatient admission datawas available
for 380 (63.1%) patients, with a total of 267 CML related drug orders. Procedures
were observed for 531 (88.2%) patients. Lab results were available for 564 (93.7%)
subjects. Of those, BCR/ABL biomarker results were available for 210 (37.2% of all
lab results) patients. CONCLUSIONS: Integrating data across different data sources
in an academic health care center with a National Comprehensive Cancer Network
hospital can provide comprehensive health care data. This methodology may in-
fluence the evolution of electronic health records, as a data resource tool for out-
comes data, resource use and cost utilization across complex disease states such as
CML. Future research will expand on drug data sourcing and evaluate the medical
record notes to evaluate CML specific outcomes.
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OBJECTIVES: In cancer research using claims data, identifying metastases is often
essential yet difficult. The objective of this study was to examine the validity of
algorithms identifying metastatic breast (BC), lung (LC), or colorectal (CRC) cancer
in healthcare claims data. METHODS: A proprietary clinical cancer database con-
taining physician-reported clinical data on patients with BC, LC, or CRC between
January 1, 2007 and March 31, 2010, was linked to claims data. Inclusion required
health plan enrollment  3 months prior to the initial clinical cancer diagnosis
date. Un-validated claims algorithms from previous research were identified. A
generic metastatic algorithm with all metastatic ICD-9 codes and tumor-specific
variations of the algorithm were assessed for validity. The algorithms’ validity
versus the clinically reported metastases was tested using sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV). RESULTS: Of
14,480 patients in the database, 4631 BC (mean age 53.6 yr), 2449 LC (mean age 62.9
yr), and 2058 CRC patients (mean age 58.3 yr) met inclusion criteria. Metastases at
diagnosis were recorded in 8.0% (371) of BC, 49.2% (1204) of LC, and 25.7% (528) of
CRC patients. The tumor specific algorithm for identifyingmetastatic BC had 53.2%
sensitivity and 98.6% specificity; PPV and NPVwere 77.6 and 95.8. The lung-specific
algorithm had 55.2% sensitivity and 85.3% specificity; PPV and NPV were 81.0 and
62.6. Similarly, the CRC-specific algorithm had 59.4% sensitivity, 89.8% specificity,
with PPV 72.9 and NPV 82.7. The generic algorithm had lower specificity and higher
sensitivity for all 3 cancers and a significantly lower PPV for breast cancer.
CONCLUSIONS: Specificity, but not sensitivity, was high for all tumor-specific al-
gorithms. Although not tested, better sensitivity might be gained by including
chemotherapy in the algorithms for some tumor types.
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OBJECTIVES: To describe the frequency of available laboratory results data in a
commercial healthcare database, among patients who are being treated for diabe-
tes or dyslipidemia and who have have at least one documented laboratory result
for a hemoglobin a1c (HbA1c) or lipid test. METHODS: The source population was
adults continuously enrolled in a large U.S. health plan during 2009 with at least
one CPT code for a HbA1c or lipid test. Laboratory results data were considered
available if LOINC codes or free text identified a result recorded within / 3 days
of the CPT claim date. The final study cohort included only patients with at least
one result available. We calculated the 1-year person-level percent of the number
of tests ordered in 2009 that had results available. Results for each test were strat-
ified by whether the patient received an antidiabetic or antidyslipidemia drug dur-
ing the same year. RESULTS: Overall, a result was available for 41% of HbA1c tests
and 42% of lipid tests. Persons with at least one prescription claim for an antidia-
betic or antidyslipidemia drug had more frequent tests recorded during the study
period (HbA1c: mean 4.5 with drug, 2.0 without drug; Lipid: mean 3.9 with drug, 2.0
without drug). However, results were less likely to be consistently available among
treated patients: 44% of those treated (among whom 70% of tests had results), and
39% of those not treated (among whom 83% of tests had results) had any results
available. CONCLUSIONS: While laboratory data may enhance studies conducted
in administrative claims databases, results may be inconsistently available. In this
study, among treated patients, 44% had any laboratory results recorded, for whom
results were missing approximately 30% of the time. An evaluation of the com-
pleteness of laboratory data prior to any study is feasible andmay help understand
any potential bias.
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OBJECTIVES: To demonstrate replication of the quantification of relationships be-
tween surrogates and endpoints as well as reconciliation with previous epidemio-
logical studies; original studies for heart rate as a surrogatefor all-cause mortality,
painmanagement and gastrointestinal adverse events, and treatment for diabetes
and HbA1c and HbA1c and complications. METHODS: For heart rate, three epide-
miological studies from three countries using aWeibull survival analysis and Gen-
eralized Estimating Equations were used; namely, the Coronary Artery Surgery
Study (CASS), the Copenhagen City Heart Study (CCHS) and the General Practitio-
ner Research Network (GPRN). These equations reproduced a meta-regression and
meta-analysis of all available placebo-controlled clinical trials with heart rate as a
prognostic factor for all-cause mortality. For pain, data consisted of 2005 Health
Care Utilization Project (HCUP) and Premier. Logistic regressions were used to ob-
tain evaluate and compare odds-ratios. In diabetes, Generalized Estimating Equa-
tions (GEE) allowing serially correlated behavior with repeated HbA1c reading at
variable frequencies and durations between theirmeasurement.RESULTS:Heart is
consistently prognostic for all-cause mortality. Moreover, its quantification is con-
sistent, 0.00694 (P0.001) in CASS and 0.00683 (P0.001) in CCHS (1981-1983) and
0.00717 in CCHS (1991-1993)with theWeibull.With theGEE, the coefficient is 0.0268
(P0.006) in GPRN, 0.0249 (P0.008) in the meta-regression of controlled clinical
trials, and 0.01595 in the GEE with CCHS data. All three equations reproduced the
published clinical trials with odd-ratios within 1/100ths.Conditional odds-ratios
were replicated in measure between the two datasets for fecal impaction, post-
operative illeus, other bowel obstruction, vomiting and abdominal pain. The dia-
betic equations were replicated exactly in 3 countries, treatment and HbA1c and
complications with coefficients within 1/100th in patients with newly diagnosed
T2DM. CONCLUSIONS: These are three studies where the quantification of the
relationship between a surrogate and and endpoint have beed replicated with
precision and subsequently applied to clinical trials.
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OBJECTIVES: This study compared the risk of developing substance use disorder in
children with Attention-Deficit/Hyperactivity Disorder (ADHD) utilizing stimulant
and atomoxetine. METHODS: This study involved retrospective, propensity score
matched cohort assessing the risk of developing substance use disorder among
stimulant and atomoxetine users with ADHD using the IMS LifeLink Health Plan
ClaimsDatabase. Adolescents between 12 and 18 years of age starting on stimulant
or atomoxetine therapy from July 1, 2004 to December 31, 2005were included in the
study sample. Substance use disorder was classified into (i) tobacco use (ICD-9-CM
code- 305.1); (ii) drug abuse (ICD-9-CM codes- 305.2-305.9, 304.x, 292.x, 304.00-
304.03, 304.70-304.73); and (iii) alcohol abuse (ICD-9-CM codes- 265.2, 303.x, 305.0,
357.5, 425.5, 291.0-291.5, 291.9, 571.0, 571.2, 571.3, 535.3, and 790.3). Patients with
stimulant and atomoxetine were matched on propensity scores calculated on the
basis of baseline characteristics. Conditional logistic model was developed using
the STRATA option to account for the matched pair design to assess the risk of
substance use disorder development. Persistencymeasured as duration of therapy
was included as a covariate in the final model along with other covariates which
were significant after matching. RESULTS: The propensity score matched cohort
consisted of 2,030 adolescents with ADHD in both the stimulant and atomoxetine
user groups (total of 4,060 adolescents). Conditional logistic regression analysis did
not show any statistically significant difference between stimulant or atomoxetine
use and the risk of substance use development (Odds Ratio [OR]- 0.86; 95% CI-
0.29-2.50). Age was the only covariate that was significantly associated with the
substance use disorder (OR-3.55; 95% CI-1.25-10.13). CONCLUSIONS: Utilization of
stimulant was not significantly associated with higher risk of substance use disor-
der compared to atomoxetine in adolescents. More research is needed to evaluate
the long-term effects of use of medications in ADHD.
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